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Zheng Xiao,1 Elizabeth Dunn*,1 Kanal Singh,1 Imran S. Khan,2 Steven M. Yannone,2
Morton J. Cowan1-/-Two Artemis-deficient (mArt ) mouse models, generated independently on 129/SvJ backgrounds, have the
expected T-B-NK1 severe combined immune deficiency (SCID) phenotype but fail to mimic the human dis-
ease because of CD41 T cell leakiness. Moreover, immune reconstitution after hematopoietic stem cell
transplantation is achieved more readily in these leaky mouse models than in Artemis-deficient humans.
To develop a more clinically relevant animal model, we backcrossed the mArt-/- mutation onto the C57Bl/
6 (B6) background (99.9%), which resulted in virtually no CD41 T cell leakiness compared with 129/SvJ
mArt1/- mice (0.3% 6 0.25% vs 19.5% 6 15.1%, P\.001). The nonleaky mouse also was uniquely resistant
to engraftment using allogeneic mismatched hematopoietic stem cells, comparable to what is seen in human
Artemis deficiency. The genetic background also influenced Artemis-associated radiation sensitivity, with
differing degrees of x-ray hypersensitivity evident in 129/SvJ and B6 backgrounds with both the mArt-/- and
mArt1/- genotypes. Our results indicate that immunogenic and DNA repair phenotypes associated with
Artemis deficiency are significantly altered by genetic background, which has important implications for
the diagnosis and treatment of SCID. Moreover, the B6 mArt-/- mouse provides a more accurate model for
the human disease and a more appropriate system for studying human Artemis deficiency and for developing
improved transplantation and gene therapy regimens for the treatment of children with SCID.
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Approximately 20% of patients with severe com-
bined immune deficiency (SCID) have a phenotype
characterized by a profound absence of both T and B
lymphocyte numbers and function but normal NK
cells, associated with a defect in the V(D)J recombina-
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6/j.bbmt.2008.10.026requires successful V(D)J recombination, through
which the germline components, V (variable), D (di-
versity), and J (joining) gene segments are assembled
to encode for V regions of immunoglobulin and T
cell receptors (TCRs) [1]. The well-characterized fac-
tors in this pathway include Ku heterodimer complex
(Ku70/86), DNA-dependent protein kinase catalytic
subunit (DNA-PKcs), XRCC4, DNA ligase IV, and
the more recently identified Artemis. The significance
of this process has been well defined by analyses of an-
imal models and some rare types of human T–B–NK1
SCID carrying germline mutations/deletions in these
genes [2-9].
Artemis mutations were identified first in children
with radiation-sensitive SCID (RS-SCID) and then in
Athabascan-speaking children with SCID (SCIDA)
[10-12]. Fibroblasts from patients with either SCIDA
or RS-SCID show increased sensitivity to ionizing ra-
diation and impaired coding joint formation
[10,12,13]. Artemis is a substrate of DNA-PKcs with
multiple phosphorylation sites in vivo and in vitro,1
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Artemis to open hairpin structures at the coding ends
of V(D)J intermediates [13-15].
An Artemis-deficient mouse model was first re-
ported in 129/SvJ mice [16]. These mice showed a sig-
nificant degree of leakiness with respect to CD41 T
cells, especially in lymph nodes, in contrast to what is
seen in children with SCID and Artemis deficiency.
Subsequently, we reported an Artemis-deficientmouse
with a mixture of 129/SvJ and B6 backgrounds (25%
and 75%, respectively) that had some degree of leaki-
ness with respect to both T cell numbers and function,
but to a more limited extent than had been reported
previously [17]. We also found significant sensitivity
to ionizing radiation in our mouse model, as well as
some resistance to allogeneic mismatched hematopoi-
etic stem cell transplantation (HSCT) that could be
overcome with nonmyeloablative doses (3 Gy) of total
body irradiation (TBI) [17].
To determine whether or not the lower level of
leakiness in our model was due to the higher percent-
age of B6 in the genetic background, we backcrossed
our original mice onto the B6 background (99.9%
B6). We also generated a 99.9% 129/SvJ with the
same Artemis mutation. The 129/SvJ mArt-/- mouse
exhibits levels of leakiness at least as high as those re-
ported previously [16]. In contrast, we found that the
phenotype of the B6 mArt-/- mouse has virtually no
leakiness and is highly resistant to allogeneic mis-
matched HSCT. In addition, we found that the Arte-
mis deletion (-/-) and haploinsufficiency (1/-) in B6
and 129/SvJ embryonic fibroblasts are significantly
different with respect to sensitivity to ionizing radia-
tion, indicating a gene dosage effect that we describe
here for the first time. Finally, unlike mArt-/- mice re-
ported previously, the phenotype of our B6 mArt-/-
mouse model closely resembles that seen in Artemis-
deficient children and thus is an appropriate model
for the human disease.METHODS
Mice
The 129/SvJ-B6mArt-/- chimericmouse (25%129/
SvJ and 75% B6) has been described previously [17].
Heterozygote (mArt1/-) male chimeric mice were
crossed with either wild-type B6 or 129/SvJ females
for an additional 7 or 8 generations to generate either
N10 B6 (99.9%) or N9 129/SvJ (99.9%) mArt-/- mice.
All references to mArt-/- are to these B6 or 129/SvJ
mice carrying the mArt-/- mutation [17] with a 99.9%
background unless indicated otherwise. C57Bl/6,
129x1/SVJ, BALB/c, and B6.SJL (CD45.1) mice were
purchased from Jackson Laboratory (Bar Harbor,
ME).All animalsweremaintained in theLaboratoryAn-
imal Resource Center (LARC) Rodent Barrier Facilityat University of California San Francisco (UCSF). All
animal procedures were approved by UCSF’s Institu-
tional Animal Care and Use Committee.
Phenotyping by Flow Cytometry
T, B, and natural killer (NK) cell and granulocyte
phenotyping and chimerism analyses were done by
flow cytometry using a FACSCalibur (BD, Franklin
Lakes, NJ), and data were processed using Cell Quest
Pro software (BD). BALB/c allogeneic (anti-H2Kd)
donor and B6 (anti-H2Kb) recipient cells or congenic
(anti-CD45.1) donor and (anti-CD45.2) recipient cells
were analyzed as previously described [18]. Peripheral
blood was obtained from the lateral saphenous vein ev-
ery 4 weeks posttransplantation, and the cells were
stained using fluorescently conjugated antibodies to
CD3, CD4, and CD8 to detect T lymphocytes and
anti-CD45R/B220 antibodies to detect B lympho-
cytes. To test for multilineage engraftment, cells
were stained with Ly6G/C, a granulocyte marker.
Leaky study mice (7 to 8 weeks old) or mice 3 to 6
months posttransplantation were euthanized and tis-
sues collected. Single-cell suspensions were prepared
from blood, spleen, thymus, lymph node, and bone
marrow and stained using the same antibodies as above.
In addition, bone marrow and spleen cells were stained
with anti-CD45R/B220 and IgM to test for mature
B cell engraftment or leakiness. Blood and spleen
cells were stained with CD49b/Pan-NK to detect
NK cells in leaky study mice. Cells were incubated
with Fc block and then antibodies for 30 minutes at
4C, washed once, and fixed in phosphate-buffered sa-
line (PBS)/1% formalin for analysis. All antibodies
were purchased from BD Biosciences Pharmingen
(San Diego, CA) or e-Bioscience (San Diego, CA).
Cell Lines and Radiation Sensitivity Assays
Mouse embryonic fibroblast (MEF) lines estab-
lished from early passage cultures were immortalized
by infection with lentivirus constructs encoding ge-
netic suppressor element (GSE)-22 (a dominant nega-
tive p53 peptide) or by introduction of SV40 large T
antigen as described previously [17,19]. Lentivirus-
infected MEF lines were selected with 1 mg/mL of
puromycin Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum (FBS), peni-
cillin (100 U/mL), and streptomycin (100 mg/mL) at
37C in a humidified incubator (5% CO2) for 7 days.
All MEF cells were maintained in the same media
without puromycin. For proliferation assays, cells
were plated in triplicate on 6-well dishes at 5 104cells
per well and irradiated using an X-ray generator (Pan-
tak, East Haven, CT) operating at 320 kV/10 mA with
0.5-mm copper filtration. Cells were recovered in the
incubator for 24 hours after radiation and then labeled
by the addition of fresh medium containing 10 mM
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MO) for an additional 24 hours, harvested, washed
with PBS, and fixed in 70% ice-cold ethanol overnight
at -20C. Cell cycle distribution and BrdU incorpora-
tion were analyzed and scored with an Easy Cyte Plus
system using Cytosoft version 3.6 cell acquisition and
analysis software (Guava, Hayward, CA). Proliferating
fraction was calculated as the percentage of intact cells
staining positive for BrdU and in G1 phase normalized
to untreated controls of the same cell line (with .
10,000 events scored for each point). Error bars are
calculated from variation among the 3 biological repli-
cates within each experiment.Hematopoietic Stem Cell Preparation and
Transplantation
BALB/c allogeneic mismatched or B6 CD45.1
congenic mice (age 2 to 4months) were used as donors.
For allogeneic and congenic HSCT, purification of
lin- c-kit1 hematopoietic stem cells (HSCs) was done
by negative selection of lineage-committed cells using
the LineageCell DepletionKit followed by positive se-
lection using CD117 microbeads (Miltenyi Biotec,
Auburn, CA) in accordance with the manufacturer’s
instructions. The lin- c-kit1 HSC preparations
were determined to be . 90% pure by flow cytom-
etry analysis.
The recipient B6mArt-/-mice were 5 to 8 weeks of
age at the time of transplantation. In each mouse,
100,000 lin–c-kit1 congenic or allogeneic mismatched
HSCs were injected i.v. through the tail vein. Most of
the mice received no previous conditioning therapy,
but 1 group was pretreated with 3 Gy of TBI using a
cesium137 animal irradiator (520A; Xetex, Sunnyvale,
CA). The mice who underwent transplantation were
maintained in the LARC Barrier Facility with antibi-
otic-supplemented water. Controls included age-
matched mArt-/-, wild-type (WT), or heterozygote
mice that received a sham injection or HSCT.In Vitro Lymphocyte Proliferation
At tissue harvest, splenocytes were collected for in
vitro lymphocyte proliferation studies. A total of 4 
106/mL post-Ficoll splenocytes were incubated in
RPMI 1640 medium (Gibco, Carlsbad, CA) contain-
ing 10% FBS and supplemented with 1 penicillin
and streptomycin (UCSF Cell Culture Facility), and
stimulated with either lipopolysaccharide (LPS) (25
mg/mL; Sigma-Aldrich) or anti-CD3 (5 mg/mL; BD
Pharmingen) in 96-well flat-bottomed plates. On day
1 (LPS) or day 2 (anti-CD3), radioisotope [H3]-thymi-
dine (PerkinElmer, Waltham, MA) was added, and the
plates were incubated for another 24 hours and then
harvested, counted, and evaluated as described previ-
ously [17].TCR Vb Quantitative Immunoscope Analysis
RNA was obtained from T cells isolated from thy-
mus or spleen using a PanTCell Positive Selection Kit
(Miltenyi Biotec). The TCR Vb repertoire analysis
was modified and performed as described previously
[20,21]. In brief, RNA was extracted and cDNA was
amplified with each of the 24 TCR Vb family mem-
ber–specific primers together with a fluorescent
(Rox) primer specific for the TCRCb segment (Super-
Script First-strand Synthesis System; Invitrogen,
Carlsbad, CA). Spectrotyping polymerase chain reac-
tion (PCR) was done with a GeneAmp PCR system
2400 (PerkinElmer). The fluorescent products were
mixed with Rox size standard (Gene Scan 500-40173;
Applied Biosystems, Foster City, CA), 99.5% formam-
ide (Sigma-Aldrich), and capillary electrophoresis was
done using an Applied Biosystems 3100 sequencer
(ABI POP4 polymer). The size and intensity of each
band were analyzed using the Genemapper version
3.0 (Applied Biosystems), following the manufactur-
er’s instructions.Enzyme-Linked Immunosorbent Assay for
Serum IgM and IgG Antibody
To measure antibody responses, mice were in-
jected i.p. with 100 mg of either NP41-Ficoll or
NP24-keyhole limpet hemocyanin (KLH) (Biosearch
Technologies, Novato CA). Postimmune serum was
collected by saphenous vein blood draw 11 days after
NP-Ficoll immunization and stored at -20C.Mice re-
ceiving NP-KLH immunizations were boosted with
an additional 100 mg of NP-KLH 5 weeks after the ini-
tial injection, and postimmune serum was collected 1
week later. NP-specific antibody response was mea-
sured by sandwich enzyme-linked immunosorbent as-
say (ELISA). MaxiSorp plates (Nunc, Rochester, NY)
were coated overnight with 5 mg/mL ofNP30-BSA (Bi-
osearch Technologies) at 4C. After washing, a block-
ing reagent (50 mMTris-buffered saline, 1% BSA; pH
8.0) was added to the wells for 1 hour, followed by
washing. Twofold serial dilutions of serum from
mice immunized with NP-Ficoll, or 4-fold serial dilu-
tions of serum from mice immunized with NP-KLH
beginning at 1:100 were added to the plates and incu-
bated for 1 hour. The plates were then washed and in-
cubated with a goat anti-mouse horseradish peroxidase
(HRP)-conjugated detection antibody for 1 hour. Af-
ter washing, HRP (Kirkegaard & Perry, Gaithersburg,
MD) was added to the plates and incubated for 20min-
utes, at which point the reaction was stopped by the ad-
dition of 4N H2SO4. Optical density was measured at
450 nm on a SpectraMax plate reader using SoftMax-
Pro software (Molecular Devices, Sunnyvale, CA).
Plates and ELISA reagents (with the exception of the
coating antigen) were included in the Mouse IgM
ELISA Quantitation Kit and the Mouse IgG ELISA
4 Biol Blood Marrow Transplant 15:1-11, 2009Z. Xiao et al.Quantitation Kit (Bethyl Laboratories, Montgomery,
TX). Optical density values for sera were measured
in duplicate and averaged, and the subsequent values
of the preimmune serum were subtracted from those
of the postimmune serum. These values were then
plotted against the corresponding dilution factor [22].Statistical Analysis
Differences in leakiness between the 2 strains of
mArt-/- mice were analyzed using either the indepen-
dent samples t test or the c2 test of goodness of fit
and independence.Figure 1. CD41 (A) or CD81 (B) T cells in 129/SvJ and B6 WT and
mArt-/- mice. Each bar represents the mean percentage (6 standard de-
viation) of CD41 or CD81 T cells gated on CD451CD31 lymphocytes
in blood, spleen, thymus, and lymph node.RESULTS
T, B, and NK Cell Phenotypes in 129/SvJ and B6
mArt-/- Mice
CD41 and CD81T cells in blood, spleen, thymus,
and lymph node were evaluated in mArt-/- mice with
either the 129/SvJ or B6 genetic background
(Figure 1A and B). The backcrossed 129/SvJ mArt-/-
mice exhibited a significantly greater degree of leaki-
ness than that previously observed in chimeric
mArt-/- mice [17], with the most striking difference
seen in the lymph nodes. (Here leakiness is defined
as$ 1%CD41 or CD81T cells.) In contrast to a pre-
vious study of 129/SvJ Artemis-deficient mice, in
which only 40% of mice were leaky [16], all of the
129/SvJ mArt-/- mice that we studied (n 5 10) ex-
hibited a leaky phenotype. CD451 lymphocytes from
129/SvJ mArt-/- mice were 19.5% 6 15.1% CD41
(range, 1.7% to 49%), whereas B6 mArt-/- T lympho-
cytes were 0.3% 6 0.25% CD41 (P\ .001). We also
compared the absolute numbers of Ficoll-purified
CD41 splenocytes in the B6 and 129/SvJ mArt-/-
mice (n 5 10 for each group) and found 3200 6
3700 CD41 T cells per spleen in the B6 mArt-/- mice
(0.07% of WT B6) and 185,000 6 220,000 (3.9% of
WT 129) in the 129/SvJ mArt-/- mice (P 5 .013). A
similar analysis of CD81 T cells demonstrated no sig-
nificant CD8 T cell leakiness in either mArt-/- group
and thus no significant difference between the 2 strains
(P 5 .496; Figure 1B).
We found variation in the amount of leakiness
among individual 129/SvJ mArt-/- mice and a notable
variation among tissues, with lymph nodes expressing
the greatest degree of leakiness (Figure 1A). Leakiness
was seen only in the CD41T cell subset in the 129/SvJ
mArt-/- mice. We noted the expected staining pattern
of CD41CD8- T cells for various tissues from leaky
129/SvJ mArt-/- mice compared with WT mice
(Figure 2). Similar to what we have found in Arte-
mis-deficient children with a null mutation [23], and
unlike in the 129/SvJ mArt-/- mice, we detectedvirtually no CD41 T cells in the nonleaky B6 mArt-/-
mice (Figure 2).
We measured NK cell content in the blood and
spleens of the B6 and 129/SvJ mArt-/- mouse strains
(n 5 3 for each group). The percentage of CD451
NK lymphocytes in blood was 84.2% 6 1.7% in the
B6 mArt-/- mice and 54.2% 6 12.1% in the 129/SvJ
mArt-/- mice. In the spleen, the NK levels were
51.9% 6 13.4% in the B6 mArt-/- mice and 32.1% 6
6.8% in the 129/SvJ mArt-/- mice. Interestingly, the
higher percentage of NK cells in the B6 mArt-/- mice
is consistent with that seen in humans with SCIDA
[23].
Leakiness Is Proportional to 129/SvJ Genetic
Contribution
We evaluated lymphocyte phenotypes in several
stages of backcrossing, including N2, N4, and N10
for B6 and N4 and N9 for 129/SvJ (Table 1). As the
percentage of the 129/SvJ background in the mice de-
clined, so did the percentage of mice that were leaky.
This trend in leakiness is closely correlated with the
percentage of 129/SvJ genetic background in all cases.
Figure 2. Flow cytometry analysis of CD41 and CD81 lymphocytes in a representative leaky 129/SvJ N9 mArt-/- mouse and nonleaky B6 N10 mArt-/-
mouse. WT B6 lymph node was used as a control. Data are expressed as number of CD41, CD81, or CD41CD81 cells gated on CD451CD31 lym-
phocytes.
Biol Blood Marrow Transplant 15:1-11, 2009 5A Non-Leaky Mouse Model of Artemis DeficiencyThe effect of 129/SvJ genetic modifiers on leakiness
was most evident when comparing . 99% 129/SvJ
mice and mice harboring identical Artemis mutations
but with # 0.1% 129/SvJ genetic content (Table 1,
top and bottom rows, respectively). Statistically signif-
icant differences in leakiness in the spleen and lymph
nodes were evident when all groups were analyzed
(P # .001).
Mouse Genetic Background Alters Artemis-
Associated Radiation Sensitivity
To assess whether the DNA repair function of Ar-
temis is similarly dependent on the mouse strain, weTable 1. Leaky Mice as a Function of Percentage of 129/SvJ in B6 G
Percent 129/SvJ CD4+Blood*
N9 129/SvJ mArt-/- (n 5 10) 99.9† 6/10
N4 129/SvJ mArt-/- (n 5 10) 95.3 1/10‡
N2 B6 mArt-/- (n 5 8) 25 1/8
N4 B6 mArt-/- (n 5 10) 6.3 0/10
N10 B6 mArt-/- (n 5 10) 0.1 0/10
Leakiness defined as$ 1% CD4+ T cells. When compared by c2 analysis for di
lymph node.
*Number of mice exhibiting leakiness in that tissue/total evaluated.
†Represents 99.9% 129/SvJ and 0.1% B6.
‡Leaky number includes 1 mouse that was leaky in the CD8 subset.evaluated the effect of Artemis deletion on the radia-
tion sensitivity of MEF cultures from both 129/SvJ
and B6 backgrounds (Figure 3). Because mechanisms
of cellular immortalization may influence radiation
sensitivity, we also performed radiation sensitivity as-
says with cells immortalized with either GSE-22 or
SV40-largeT antigen, as well as cells derived from sev-
eral different animals to control for intra-animal vari-
ations. We found that cells from B6 mice appeared to
be less sensitive to radiation effects in this assay than
cells from 129/SvJ mice. As expected, the homozygous
Artemismutants were themost sensitive to ionizing ra-
diation relative to the other genotypes tested in bothenetic Background
CD4+Spleen* CD4+Thymus* CD4+Lymph Node*
7/10 7/10 10/10
4/10‡ 2/10 10/10‡
1/8 2/8 Not available
0/10 0/10 1/10
0/10 0/10 0/10
fferences among groups 99.9%/0.1%, P5 .001 for spleen and .0001 for
Figure 3. Radiation sensitivity assays. MEFs were scored for proliferation 48 hours after X-ray exposure based on BrdU containing G1 cells relative to
untreated controls. Cell line details are identified by cell line number, mouse strain, and Artemis genotype. (A) Radiation sensitivity of GSE-22–trans-
formedmArt1/1,mArt1/-, andmArt-/- on the 129/SvJ background. (B) Radiation sensitivity of GSE-22–transformedmArt1/1, mArt1/-, andmArt-/- on the B6
background. (C) Radiation sensitivity of SV40-transformed mArt1/1, mArt1/-, and mArt-/- on the 129/SvJ background, derived from different animals. (D)
Radiation sensitivity of additional mArt-/- lines from additional animals of noted backgrounds immortalized with GSE-22 (top) or SV40 (bottom).
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crease in radiation sensitivity in the Artemis null muta-
tion relative to the WT mice was more pronounced in
the 129/SvJ background than in the B6 background
(Figure 3; compare A, B, and C). This greater sensitiv-
ity in 129/SvJ was consistently evident in multiple cell
lines when 129/SvJ and B6 mArt-/- were compared di-
rectly in both GSE and SV40 immortalized cells
(Figure 3D). Our evaluation of the effects of radiation
on heterozygous cells from each strain revealed an in-
termediate response between the WT and null. As in
the case of the null mutants, Artemis haploinsuffi-
ciency in the 129/SvJ background conferred increased
radiation sensitivity relative to the WT, whereas the
identical heterozygous mutation in B6 was not signif-
icantly different from that in the WT (compare Fig-
ures 3A and B). The increased sensitivity of theheterozygous Artemis mutant also was evident in a sec-
ond set of 129/SvJ cell lines from different animals im-
mortalized with SV40 rather than GSE-22
(Figure 3C).Congenic and Allogeneic HSCT in Nonleaky B6
mArt-/- Mice
We carried out transplantation studies to assess the
impact of the B6 background on the outcome of vari-
ous BMT regimens. HSCT using 1  105 lin-c-kit1
congenic donor cells (CD45.1) in young adult B6
mArt-/- recipients (CD45.2) resulted in T cell, but
not B cell, reconstitution, with T cell numbers increas-
ing over time (Table 2; Figure 4). However, whenmice
were pretreated with a nonmyeloablative dose of radi-
ation (3 Gy TBI), significant numbers of donor B cells
Table 2. T Cell, B Cell, and Granulocyte Engraftment in Blood in B6 mArt-/- Mice after Congenic and Allogeneic HSCT
BMT
Marrow Preparation and
Preconditioning
1 Month Post-HSCT 2 Months Post-HSCT At Least 3 Months Post-HSCT
T cells,%* B cells,%* T cells,%* B cells,%* T cells,%* B cells,%* Granulocytes, %†
Congenic (CD45.1) HSCs‡ (n 5 6) 4.0 ± 2.7 0 16.3 ± 4.1 0 64.4 ± 8.2 0 NA
Congenic (CD45.1) HSCs‡/TBI (n 5 4) 44.6 ± 3.5 18.4 ± 2.8 56.6 ± 4.5 23.5 ± 7.0 46.1 ± 2.2 35.2 ± 2.1 64.1 ± 11.2
Allogeneic (BALB/c) HSCs‡ (n 5 5) 0 0 0 0 NA NA available NA
Allogeneic (BALB/c) HSCs‡/TBI (n 5 4) 1.8 ± 1.2 (3)§ 3.3 ± 1.5 (3)§ 4.4 ± 3.4 (2)§ 3.4 ± 0.7 (2)§ NA NA available NA
NA, Not available.
WTmice used as controls had a mean percentage of 28.5%6 17.7% CD3+ (T cells) and 37.5%6 2.1% CD45R/B220+ (B cells) in the CD45+ lymphocyte
gate.
*Mean percentage of CD3+ (T cells) or CD45R/B220+ (B cells) in the CD45+ lymphocyte gate 6 standard deviation.
†Mean percentage of donor granulocytes of total granulocytes 6 standard deviation.
‡For HSCs (lin–c-kit+), 1  105 cells were injected. Mice treated with TBI received 3 Gy.
§Mean 6 standard deviation of engrafted animals. The number in parentheses is the number of HSCTrecipients that engrafted ($ 0.75% donor cells).
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congenic HSCT (Table 2). Donor engraftment of
these cells persisted for more than 5 months posttrans-
plantation (Table 2). Further phenotyping analyses re-
vealed that congenic HSCT recipients with and
without TBI pretreatment developed CD41 and
CD81 T cells in the peripheral blood, spleen, lymph
nodes, and thymus, as well as CD41CD81 T cells in
the thymus, comparable to those seen in WT controls
(Figure 4). With respect to B cell reconstitution,
IgM1B2201 cells were present only in the bone mar-
row of congenic HSCT recipients who received TBI
(Figure 4). HSCT using 1  105 allogeneic mis-
matched (BALB/c) donor HSCs resulted in no donor
cell engraftment (Table 2).When the B6mArt-/- recip-
ient mice were pretreated with low-dose TBI, a degree
of T and B cell engraftment occurred, but at a much
lower level than that seen with congenic donor cells.Tand B Cell Proliferative Responses in Leaky
and HSCT Recipient Mice
We evaluated the proliferative responses of 129/
SvJ mArt-/- leaky T and B cells to either anti-CD3
MoAb or LPS, a B cell mitogen (Figure 5A). The re-
sponse to anti-CD3 MoAb in the 129/SvJ mArt-/-
mice was an average of 9.5% (13,617 6 9379 cpm) of
normal WT littermate controls, and all 9 mice tested
had a response ranging from 0.9% to 19.4%of control.
The proliferative response of cells from leaky mice to
LPS was less apparent, averaging only 1.0% (1619 6
2325 cpm) of that seen in normal controls. Only 3 of
7 mice tested exhibited any B cell response, with the
highest response of the 3 being 3.5% of normal. The
nonleaky B6 mArt-/- mice exhibited virtually no re-
sponse to either anti-CD3 or LPS.
We also evaluated lymphocyte proliferative re-
sponses to anti-CD3 and LPS in the 2 congenic
HSCT groups (6 300 cGy TBI). Near-normal prolif-
erative responses to anti-CD3 stimulation were seen in
the recipients of congenic HSCT, whereas the re-
sponses to LPS were absent (Figure 5A). When 3 GyTBI was added to the preparative regimen, the prolif-
erative responses to both anti-CD3 and LPS stimula-
tion were normal (Figure 5A).TCR Vb Repertoire in Leaky and HSCT
Recipient Mice
To roughly approximate the baseline frequency of
successful V(D)J recombination in the leaky mice, we
assessed the TCR Vb repertoire in the T cells from
these animals. In the 129/SvJ mArt-/- mice, clonal pat-
terns were observed in all 4 of the regions analyzed, un-
like the normal Gaussian distribution of the different
CDR3 lengths in WT mice (Figure 5B). A compara-
tive TCR Vb repertoire analysis for B6 mArt-/- mice
was not possible due to the absence of T cells.
We also analyzed the TCR Vb repertoire in en-
grafted circulating T cells of congenic HSCT mice.
Although these mice exhibited T cell numbers in the
normal range by 3 months posttransplantation (see
Table 2), the T cell repertoires had skewed profiles
or clonal patterns in the immunoscope analysis, indi-
cating preferential and restricted clonal expansion of
the engrafted T cells whether or not low-dose TBI
was used (Figure 5B).Serum IgM and IgG Responses in HSCT
Recipient Mice
We assayed B cell function in the congenic HSCT
recipients by measuring serum IgM-specific antibody
production. In congenic recipients that were not
treated with TBI, immunization with the T cell–
independent antigenNP-Ficoll did not elicit a humoral
response (Figure 5C). In the congenic group treated
with TBI, serum IgM-specific antibody was detected
in response to immunization with the T cell–
dependent antigen NP-KLH (Figure 5D). Specific
IgG antibody to NP-KLH also was detected in these
recipients (data not shown).
Figure 4. Immune reconstitution in a representative B6 WT mouse, a mArt-/-mouse, a mArt-/- mouse that underwent congenic HSCT, and a mArt-/-
mouse that underwent congenic HSCT treated with TBI (3 Gy). T cell phenotyping was performed on tissues (peripheral blood [PB], spleen, lymph
node [LN], and thymus) collected$ 3 months posttransplantation. B cell phenotyping was done on bone marrow (BM). Data are expressed as number
of CD41, CD81, or CD41CD81 cells gated on CD31 lymphocytes. Mature B cells (IgM1 B2201) and immature B cells (IgM- B2201) were gated on
lymphocytes.
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Leakiness versus Nonleakiness
Two independently generated mArt-/- mouse
models [16,17] failed to faithfully replicate the pheno-
types seen in Artemis-deficient humans, thereby limit-
ing the utility of these mouse models in developing
improved clinical regimens. We found that by back-
crossing the mArt-/- mutation [17] onto the B6 mouse
(99.9%), we were able to generate a nonleaky mouse
model of Artemis-deficient SCID with respect to
both T cell numbers and function that also expresses
significant graft resistance in response to allogeneicmismatched HSCT. The leakiness in our Artemis-
deficient 129/SvJ mice is similar to that reported by
Rooney et al. [16], except that in their model, the defi-
cient mice were shown to have significant leakiness
with respect to CD41 cells in the lymph nodes from
only 4 of the 10 mice studied. In contrast, we found
CD41T cells in the lymph nodes of all 10 of the back-
crossed 129/SvJ mArt-/- mice that we studied. Our re-
sults unambiguously show that the mouse genetic
background proportionally alters the phenotypes asso-
ciated with Artemis deficiency. Spectrotyping patterns
revealed a very limited TCR repertoire in the leaky T
cells, indicating impaired T cell development and
Figure 5. Tand B cell proliferative responses, TCR diversity, and specific IgM response posttransplantation. (A) Proliferative responses of lymphocytes
to anti-CD3 antibody and LPS. B6 WT mice (positive controls) and mArt-/- mice (negative controls) were compared with recipients of congenic HSCT
with and without TBI at$ 3 months posttransplantation. Results (stimulated minus resting) are expressed as counts per minute (cpm) on a log scale. (B)
TCR Vb repertoire analysis. T cells were enriched from either thymus or spleen and prepared as described in Materials and Methods. Four represen-
tative Vb regions are shown from a representative B6WTmouse, a leaky 129/SvJmArt-/-mouse, 2mArt-/- recipients of congenic HSCT (451 and 454), and
2mArt-/- recipients of congenic HSCTwith TBI (658, 660). (C) Serum IgM-specific antibody response to NP-Ficoll after immunization (minus preimmune
response). The figure shows the average response from recipients (n5 4) of congenic HSCTat$ 3 months posttransplantation. B6mArt1/- (n5 7) and
B6 mArt-/- (n 5 4) mice were used as positive and negative controls, respectively. (D) Serum IgM-specific antibody response to NP-KLH after immuni-
zation (minus preimmune response). The average response from recipients (n5 3) of congenic HSCTwith TBI (3Gy) is compared with that of B6mArt1/-
(n 5 3) and B6 mArt-/- (n 5 3) controls.
Biol Blood Marrow Transplant 15:1-11, 2009 9A Non-Leaky Mouse Model of Artemis Deficiencyclonal outgrowth. Finally, although the lymphocyte
function in the spleens from our 129/SvJ mArt-/-
mice was10% of that seen in theWTmice and com-
parable to what we had reported previously in 129/B6
chimeric mArt-/- mice [17], our B6 Artemis-deficient
mice exhibited no lymphocyte function, similar to
what is seen in human Artemis deficiency.
Although the leakiness in this model is reflected
principally in the CD4 subset, in the 10 129/SvJ N4
mArt-/- (95.3 % 129/SvJ) mice that we studied, 1
mouse expressed primarily CD81 T cells and 3 mice
had mature B cells in the bone marrow (data not
shown). This indicates that the mechanism(s) that al-
lows the escape of lymphocytes past the block in mat-
uration affects all subsets, although the effect clearly is
greatest on CD4 cells.
Consistent with this idea of a general escape mech-
anism, we found differences in the radiation sensitivity
of cell lines from 129/SvJ and B6 backgrounds. Most
notably, cells from heterozygote 129/SvJ mArt1/-
mice showed a gene dosage effect, with an intermedi-
ate radiation sensitivity between that of the WT and
null mice, whereas the same haploinsufficiency in the
B6 background lacked distinction compared withWT. Moreover, like the differences in leakiness in
these backgrounds, the Artemis null cells were more
radiation-sensitive on the 129/SvJ background than
on the B6 background.
Together, these data indicate that the genetic
background significantly modifies both immunologic
and DNA repair phenotypes associated with Artemis
deficiencies, although in somewhat different ways. Cu-
riously, relative to the B6 background, Artemis defi-
ciency in the 129/SvJ background better repairs
V(D)J intermediates, manifesting as leakiness, yet
less efficiently repairs radiation-induced damage, man-
ifesting as more pronounced radiation sensitivity. Al-
though the mechanism for this disparity is not clear,
we propose several plausible reasons for this apparent
contradiction: (1) Failed V(D)J recombination in-
volves 1 double-strand DNA break per cell, with 1
type of terminus, whereas radiation damage causes
far more breaks and a wide spectrum of termini; (2) re-
pair and survival processes in fibroblasts and lympho-
cytes are not equivalent; (3) repair processes other
than nonhomologous end joining may account for
the leakiness (ie, homologous recombination), but
these may not compensate for Artemis deficiency in
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terestingly, we did not find tumor formation in any
of the animals with or without radiation exposure, al-
though it is possible that we did not follow them
long enough to detect this side effect.
In any case, clearly, both the immunologic and
DNA repair/radiation survival functions of Artemis
are significantly affected by the genetic background.
These findings have implications for the diagnosis
and treatment of Artemis defects in humans. Specifi-
cally, the possibility exists that some carriers of Arte-
mis mutation may have increased sensitivity to
radiation and chemotherapy with alkylating agents
and/or be at increased risk for cancer. In addition,
the leakiness in Artemis-deficient mice also may be-
come evident in some affected humans, potentially
confounding the correct diagnosis. Finally, the leaki-
ness in the mArt-/- mice closely corresponds with the
degree of 129/SvJ in the background. These results
suggest that genetic modifiers exist in the 129/SvJ ge-
netic background that permit low-level resolution of
V(D)J intermediates, resulting in at least some T and
B lymphocyte differentiation despite Artemis defi-
ciency.
Graft Resistance and Disparate Tand B Cell
Reconstitution after HSCT
We previously reported significant T cell and
some B cell engraftment in the leaky 129/SvJ mArt-/-
mice after congenic HSCT with or without low-dose
TBI conditioning. These results were significantly dif-
ferent from our findings in the nonleaky B6 mArt-/-
mice in which no B cell reconstitution occurred.More-
over, we found that, in contrast to our previous chime-
ric (25% 129/SvJ) model [17], in which 4 104 donor
BALB/c HSCs (lin-Sca11) resulted in T cell, but not B
cell, engraftment, the nonleaky B6 mArt-/- mice were
completely resistant to engraftment with 1  105 allo-
geneic mismatched BALB/c HSCs. Even when low-
dose TBI was used, the nonleaky mice recovered T
and B cell immunity to only a limited extent, much
less than that seen in the chimeric mice [17]. The dif-
ferent engraftment results after allogeneic HSCT in
the B6 mArt-/- mouse and our previous 129/SvJ-B6
mArt-/- chimeric mouse model (25% 129/SvJ) likely
reflect the impact of the genetic background [17]. Se-
quence comparison of conserved genes indicates that
Ly49 receptors in 129/SvJ and BALB/c are more
closely related to each other than to the corresponding
B6 Ly49 receptor [24,25]. NK cells use inhibitory
Ly49 receptors to differentiate self from foreign cells
based on interactions with major histocompatibility
class I molecules. Thus, BALB/c donors potentially
are less likely to be rejected in leaky 129/SvJ mArt-/-
mice than in B6 mArt-/- mice. It is interesting that
the T cells in the leaky animals that we studied earlier
[17] did not appear to increase graft resistance. We as-sessed the TCRVb repertoire in the T cells from leaky
129/SvJmArt-/-mice and found clonal patterns in all 4
of the regions analyzed, unlike the normal Gaussian
distribution of the different CDR3 lengths in WT
mice, indicating that the leaky CD41 T cells are not
fully functional. Therefore, we assume that the pres-
ence of NK cells is the critical factor in the graft resis-
tance in these animals and that the leaky T cells play
little or no role.
B6 mArt-/- SCID Mice Are Comparable to
Children with Artemis Deficiency
The very high incidence of T-B-NK1 SCID in
Athabascan-speaking children is associated with
a founder mutation in Artemis [11,26]. We previously
reported our experience with transplantation in a large
number of Athabascan-speaking Navajo children with
this mutation [23]. Not only do these children have
a virtual absence of T and B cells in both numbers
and function, but their fibroblasts show increased sen-
sitivity to ionizing radiation, and they have clinical
manifestations of increased sensitivity to alkylating
agents and radiation. In addition, transplants from
HLA-matched siblings (differing in minor HLA anti-
gens) usually result in T cell, but not B cell, reconstitu-
tion [23], similar to congenic transplants in the B6
mArt-/- mice model, because CD45.1 congenic mar-
row is major histocompatibility complex–matched to
CD45.2 mice except for a minor H antigen mismatch.
When allogeneic mismatched (BALB/c) HSCs are
used, the B6 mArt-/- mice are resistant, comparable
to children with Artemis deficiency, who typically
reject haplocompatible stem cell–enriched, T cell–de-
pleted grafts unless some kind of conditioning therapy
is used. Those who receive marrow ablative therapy
and/or TBI reconstitute both T and B cell immunity.
But relatively few survive the harsh conditioning treat-
ments, presumably because of their increased sensitiv-
ity to alkylating agents and ionizing radiation. Not
surprisingly, when we exposed the B6 mArt-/- mice to
higher doses of nonablative radiation (6 Gy TBI) fol-
lowed by HSCT, the mortality was 100% (data not
shown).
In summary, our results demonstrate that the im-
munologic leakiness and radiation sensitivity of
mArt-/- mice are strain-dependent. We found a dose
dependency of leakiness in terms of the amount of
129/SvJ background in the mice, suggesting gene dos-
age effects with these Artemis genetic modifiers. We
found that Artemis haploinsufficiency increased radia-
tion sensitivity, but this effect was less evident in the B6
background. In addition, the B6 mArt-/- mice showed
significant resistance to allogeneic HSCT; there was
no engraftment without conditioning and only limited
engraftment when low-dose TBI was used as condi-
tioning, significantly different from what we saw in
the leaky mouse model [17]. Even with congenic
Biol Blood Marrow Transplant 15:1-11, 2009 11A Non-Leaky Mouse Model of Artemis DeficiencyHSCT, the B6 mArt-/- mice exhibited only T cell re-
constitution, whereas the leaky mice exhibited both
T cell and B cell reconstitution. In all phenotypes as-
sessed, the B6 mArt-/- mouse model reported here
more closely mimics the phenotypes seen in Athabas-
can-speaking children with Artemis deficiency [23].
Thus, this B6 mArt-/- mouse model will be extremely
useful in developing more efficacious treatment regi-
mens, including gene therapy, to reconstitute the im-
mune systems of Artemis-deficient children.ACKNOWLEDGMENTS
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